Dosage ; See Below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Pradaxa | Boehringer Ingelheim International | Pharma Specialities Ltd. | 75mg | 30 | Capsule | per capsule | KES 3,719.00 |
| Pradaxa | Boehringer Ingelheim International | Pharma Specialities Ltd. | 75mg | 60 | Capsule | per capsule | KES 7,437.00 |
| Pradaxa | Boehringer Ingelheim International | Pharma Specialities Ltd. | 110mg | 30 | Capsule | per capsule | KES 3,719.00 |
| Pradaxa | Boehringer Ingelheim International | Pharma Specialities Ltd. | 110mg | 60 | Capsule | per capsule | KES 7,,437.00 |
| Pradaxa | Boehringer Ingelheim International | Pharma Specialities Ltd. | 150mg | 60 | Capsule | per capsule | KES 7,437.00 |
|
Dagibatran More info |
|
|---|---|
| Mode Of Action | Direct thrombin inhibitor anticoagulants |
| Drug Indication | Prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery. |
| Precautions | Elderly; body-weight less than 50 kg; recent surgery; anaesthesia with postoperative indwelling epidural catheter (risk of paralysis give initial dose at least 2 hours after catheter removal and monitor neurological signs); bacterial endocarditis (increased risk of bleeding); bleeding disorders; active gastrointestinal ulceration; concomitant use of drugs that increase risk of bleeding. |
| Contra-Indications | Active bleeding; impaired haemostasis. |
| Side Effects | Haemorrhage, hepatobiliary disorders. |
| Dosage | Prophylaxis of venous thromboembolism following total knee replacement surgery, adult over 18 years, 110 mg (elderly over 75 years, 75 mg) 1-4 hours after surgery, then 220 mg (elderly over 75 years, 150 mg) once daily for 9 days. Prophylaxis of venous thromboembolism following total hip replacement surgery, adult over 18 years, 110 mg (elderly over 75 years, 75 mg) 1-4 hours after surgery, then 220 mg (elderly over 75 years, 150 mg) once daily for 27-34 days. Note: Max. 150mg daily with concomitant amiodarone or verapamil. |
| Special Information | It is a direct thrombin inhibitor taken orally. |
| Pregnancy Category | Category D |
| Pregnancy Category Description | Drugs, which have caused, are suspected to have caused, or may be expected to cause an increased rise in the frequency of malformations or irreversible damage. These drugs may also have adverse pharmacological effects required required |
| Drug Category | DRUGS ACTI NG ON THE CARDIO-VASCULAR SYSTEM |
| Drug Sub-Category | Oral anti-coagulants |